AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
deoxycholic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4988 | 83-44-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.760 | Moderate | 0.77 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.442 | Moderate | 0.77 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 54.325 | 10^-6 cm/s | Moderate | 0.77 |
| dh-clint | Dog hepatocyte intrinsic clearance | 10.839 | uL/min/10^6 cells | Moderate | 0.77 |
| dppb | Dog plasma protein binding (% unbound) | 1.760 | % | Moderate | 0.77 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 5.820 | % | Moderate | 0.77 |
| herg | hERG pIC50 | 4.643 | pIC50 | Moderate | 0.77 |
| hh-clint | Human hepatocyte intrinsic clearance | 4.519 | uL/min/10^6 cells | Moderate | 0.77 |
| hlm-clint | Human liver microsomal intrinsic clearance | 4.055 | uL/min/mg protein | Moderate | 0.77 |
| hppb | Human plasma protein binding (% unbound) | 2.410 | % | Moderate | 0.77 |
| kinase-safety-class | ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 16 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.198 | Moderate | 0.77 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 25.119 | Moderate | 0.77 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.900 | Moderate | 0.77 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 15.959 | Moderate | 0.77 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.350 | % | Moderate | 0.77 |
| rh-clint | Rat hepatocyte intrinsic clearance | 31.769 | uL/min/10^6 cells | Moderate | 0.77 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 31.770 | % | Moderate | 0.77 |
| rppb | Rat plasma protein binding (% unbound) | 3.950 | % | Moderate | 0.77 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 866.962 | uM | Moderate | 0.77 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 29, 2015 | FDA | KYTHERA BIOPHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Injection site swelling | 362.23 | 102.50 | 99 | 1385 | 59740 | 90567223 |
| Facial paresis | 289.96 | 102.50 | 51 | 1433 | 3912 | 90623051 |
| Injection site nodule | 225.44 | 102.50 | 42 | 1442 | 4431 | 90622532 |
| Nerve injury | 198.34 | 102.50 | 44 | 1440 | 11062 | 90615901 |
| Injection site pain | 178.38 | 102.50 | 76 | 1408 | 173623 | 90453340 |
| Swelling | 172.31 | 102.50 | 98 | 1386 | 418960 | 90208003 |
| Injection site induration | 157.11 | 102.50 | 36 | 1448 | 10432 | 90616531 |
| Injection site mass | 116.67 | 102.50 | 33 | 1451 | 22057 | 90604906 |
| Facial asymmetry | 109.28 | 102.50 | 18 | 1466 | 922 | 90626041 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Injection site swelling | 260.63 | 76.08 | 65 | 749 | 61725 | 110526760 |
| Injection site nodule | 146.93 | 76.08 | 26 | 788 | 4620 | 110583865 |
| Facial paresis | 146.22 | 76.08 | 27 | 787 | 6086 | 110582399 |
| Injection site pain | 102.49 | 76.08 | 41 | 773 | 177881 | 110410604 |
| Nerve injury | 102.26 | 76.08 | 22 | 792 | 10691 | 110577794 |
| Swelling | 93.16 | 76.08 | 47 | 767 | 350994 | 110237491 |
| Injection site induration | 78.94 | 76.08 | 18 | 796 | 11365 | 110577120 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D11AX24 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals |
| FDA PE | N0000008476 | Decreased Cell Membrane Integrity |
| MeSH PA | D002756 | Cholagogues and Choleretics |
| MeSH PA | D005765 | Gastrointestinal Agents |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:85234 | human blood serum metabolite |
| FDA EPC | N0000191548 | Cytolytic Agent |
Related Drugs by ATC class:
D11AX Other dermatologicals 20 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Excess subcutaneous fat | indication | 248302001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.92 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 7622130 | Dec. 10, 2027 | METHOD FOR REDUCTION OF SUBMENTAL FAT |
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 7754230 | Dec. 10, 2027 | METHOD FOR REDUCTION OF SUBMENTAL FAT |
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 8546367 | Feb. 21, 2028 | METHOD FOR REDUCTION OF SUBMENTAL FAT |
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 9522155 | Feb. 21, 2028 | IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING |
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 9636349 | Feb. 21, 2028 | IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING |
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 9949986 | Feb. 21, 2028 | IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING |
| 20MG/2ML (10MG/ML) | KYBELLA | ABBVIE | N206333 | April 29, 2015 | RX | SOLUTION | SUBCUTANEOUS | 12161653 | Feb. 17, 2032 | IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| fMet-Leu-Phe receptor | GPCR | ANTAGONIST | Ki | 4 | IUPHAR | ||||
| Bile acid receptor | Nuclear hormone receptor | EC50 | 4.35 | CHEMBL | |||||
| G-protein coupled bile acid receptor 1 | GPCR | AGONIST | EC50 | 6.20 | IUPHAR | ||||
| Steroid Delta-isomerase | Enzyme | Kd | 4.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 005990WHZZ | UNII |
| 4018928 | VANDF |
| 4035848 | VANDF |
| C0011479 | UMLSCUI |
| CHEBI:28834 | CHEBI |
| DHO | PDB_CHEM_ID |
| CHEMBL406393 | ChEMBL_ID |
| 222528 | PUBCHEM_CID |
| DB03619 | DRUGBANK_ID |
| CHEMBL412272 | ChEMBL_ID |
| CHEMBL1208257 | ChEMBL_ID |
| CHEMBL514674 | ChEMBL_ID |
| D003840 | MESH_DESCRIPTOR_UI |
| 9540 | INN_ID |
| 610 | IUPHAR_LIGAND_ID |
| DB05780 | DRUGBANK_ID |
| 1367220 | RXNORM |
| 14975 | MMSL |
| 234529 | MMSL |
| d08364 | MMSL |
| 001205 | NDDF |
| 010267 | NDDF |
| 781373006 | SNOMEDCT_US |
| 78258003 | SNOMEDCT_US |
| CHEMBL453873 | ChEMBL_ID |
| 005990WHZZ | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| KYBELLA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61168-101 | INJECTION, SOLUTION | 20 mg | SUBCUTANEOUS | NDA | 26 sections |